Global diabetes drugs market set for 9.7pc annual growth
TechNavio's latest report looks at the potential for growth in the diabetes drugs market.
The global market for diabetes drugs will grow at a compound annual growth rate (CAGR) of 9.7 per cent between 2011 and 2015, analysts have predicted.
TechNavio's latest report highlights the rising number of people with diabetes as the key driver behind the trend, with increasing urbanisation and sedentary lifestyles contributing to the disease's growing prevalence in both developed and low-income countries.
In addition, analysts noted that there is increasing awareness of diabetes and the importance of treating the disease effectively, thanks to public campaigns and education programmes.
"The number of such campaigns is increasing worldwide, and the awareness level among the worldwide population is set to increase in the near future," a spokesperson for TechNavio's healthcare team said.
"Market growth is expected to be fuelled by improved education regarding the importance of blood glucose management.''
The report also highlights a number of key players in the global diabetes drugs market, namely Eli Lilly and Co, Merck and Co, Novo Nordisk and Sanofi.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News From Pharma to Table? Direct-to-consumer pharma sales and price cuts ramp up in US
The pharmaceutical industry is witnessing a seismic shift as major companies embrace direct-to-consumer sales models and announce significant price reductions across the United States, responding to mounting pressure from the Trump administration to ta... -
News A Day in the Life of a Director of Business Development
In this Day in the Life of interview, Thomas Hauser, Director of Business Development at Tjoapack. Thomas has spent nearly 30 years in the pharmaceutical industry and describes how he still finds curiosity and excitement in the bigger picture of global... -
.png)
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective.